INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc. - IBRX

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving ImmunityBio, Inc. and its officers or directors [1] Group 1: Company Developments - On January 23, 2026, ImmunityBio announced updated Phase 2 clinical results from the QUILT 3.078 trial, which focuses on a chemotherapy-free combination immunotherapy for patients with recurrent or progressive glioblastoma [3] - The press release indicated that the median overall survival, the primary endpoint of the trial, has not yet been reached [3] - Following this announcement, ImmunityBio's stock price decreased by $0.89 per share, representing a 12.13% decline, closing at $6.45 per share on the same day [3] Group 2: Legal Investigation - Pomerantz LLP is reaching out to investors of ImmunityBio to discuss claims related to potential securities fraud [1] - The firm is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud and corporate misconduct [4]